Replies to post #37996 on OncoSec Medical Inc (ONCSQ)

[hschlauch]

The UCSF metastatic melanoma exploratory and validation studies with pembrolizumab monotherapy demonstrated that 0% of patients with <20% CTLA-4hi/PD-1hi CD8 TIL phenotypes responded to Pembrolizumab; 60% of patients with 20%-30% CTLA-4hi/PD-1hi CD8 TIL phenotypes did respond to Pembrolizumab; and 100% of patients with >30% CTLA-4hi/PD-1hi CD8 TIL phenotypes responded to Pembrolizumab.

I want to see how much of a change immunopulse IL-12 can make in these exhausted phenotype percentages for CD8 TIL. We know that, based on interim phase 2 data, immunopulse IL-12 is able to convert 40% of predicted non-responders into responders (and some of these patients were actual non-responders to a variety of prior therapies including pembrolizumab). ARE THEY PRIMING THESE PATIENTS FOR PEMBROLIZUMAB BY ACTUALLY ELEVATING THEIR CTLA-4hi/PD-1hi CD8 TIL PHENOTYPE PERCENTAGES ABOVE 20%?